Aprea Therapeutics (APRE) Capital Expenditures (2018 - 2024)

Aprea Therapeutics (APRE) posted quarterly Capital Expenditures of $7500.0 for Q2 2024, down 5.99% quarter-over-quarter from $7978.0 in Q1 2024.

Aprea Therapeutics (APRE) Capital Expenditures (2018 - 2024) Analysis & Trends

Aprea Therapeutics (APRE) has reported Capital Expenditures for 5 consecutive years, with $7500.0 the latest figure, recorded in Q2 2024.

In Q2 2024, Capital Expenditures changed N/A year-over-year to $7500.0; the TTM figure through Dec 2024 stood at $15478.0 (down 25.21% YoY), while the FY2024 annual figure was $15478.0, down 83.37% from the prior year.
Capital Expenditures eased to $7500.0 in Q2 2024 per APRE's latest filing, from $7978.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $16290.0 in Q4 2020 and bottomed at -$2021.0 in Q2 2020.
Historically, Capital Expenditures has averaged $6905.3 across 3 years, with a median of $7500.0 in 2024.
On a YoY basis, Capital Expenditures climbed as much as 12.61% in 2020 and fell as far as 107.08% in 2020.
Aprea Therapeutics' Capital Expenditures stood at $16290.0 in 2020, then tumbled by 56.11% to $7150.0 in 2023, then grew by 4.9% to $7500.0 in 2024.
Business Quant data shows APRE's Capital Expenditures at $7500.0 in Q2 2024, $7978.0 in Q1 2024, and $7150.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Aprea Therapeutics	34.25 Mn	34.25 Mn	-	-

Download Data